Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis
Joyutpal Das(Sheffield Teaching Hospitals NHS Foundation Trust), Basil Sharrack(Sheffield Teaching Hospitals NHS Foundation Trust), Sona Mistry(Sheffield Teaching Hospitals NHS Foundation Trust), Richard K. Burt(Northwestern University), Harold Atkins(University of Ottawa), John A. Snowden(Sheffield Teaching Hospitals NHS Foundation Trust), Chiara Innocenti(Azienda Ospedaliero-Universitaria Careggi), Riccardo Saccardi(Azienda Ospedaliero-Universitaria Careggi), Helen Jessop(Sheffield Teaching Hospitals NHS Foundation Trust), Joachim Burman(Uppsala University), MS Freedman(Ottawa University), PJ Laud(University of Sheffield), Marjorie A. Bowman(United States Department of Veterans Affairs)
Cited by 43
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Differential diagnosis of suspected multiple sclerosis: a consensus approach
|Multiple Sclerosis Journal|2008|643